Antibiotics, Microbiology and Immunology in Children With Chronic Wet Cough - the AMIC Study

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Protracted Bacterial Bronchitis

In brief

The AMIC study is a double-blind, placebo-controlled, multicenter, nationwide, randomized controlled academic pharmaceutical trial. OVERALL PRIMARY OBJECTIVES: * To study the clinical efficacy of antibiotics in children with chronic wet cough (CWC). * To study if duration of treatment with antibiotics in children with CWC has impact on efficacy or time to relapse of symptoms. OVERALL SECONDARY OBJECTIVE: -To study respiratory pathogens and the diversity/composition of airway and gut microbiome in children with CWC compared to healthy controls, and changes in pathogens/microbiome after treatment with antibiotics. OVERALL TERTIARY OBJECTIVE: -To study the role of inflammation, immunology, and genetics in children with chronic wet cough and suspicion of PBB to increase the knowledge of pathophysiological mechanisms associated with PBB. The study will include two different RCTs AMIC 1 and AMIC 2: AMIC 1: Participants will be randomly assigned to 14 days amoxicillin-clavulanate syrup or placebo. AMIC 2: Participants will be randomly assigned 1:1 to receive either 14 or 28 days with amoxicillin-clavulanate syrup.

Key facts

Study ID

NCT06020716

Run by

Helse Stavanger HF

People needed

350

Starts

2023-08-16

Expected to finish

2028-04-30

Last updated by the study team

2024-12-27

Who can join

Age: 1 and older, up to 3. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age ≥ 9 and < 36 months.
• Body weight ≥ 7 kg and < 24 kg.
• Born term with Gestational age ≥ 37 weeks.
• Chronic wet cough for > 4 weeks at screening and in addition average cough score last 7 days at randomization ≥ 4 points and without signs of another cause. Registration ≥ 5 days is mandatory.
• Written informed consent obtained from both parents at inclusion.
• The study subject must be assessed as eligible for treatment with Augmentin.

You may not qualify if…

• Gestational age < 37 weeks.
• History of acute upper or lower airway infection the last 2 weeks.
• History of other viral or bacterial infections the last 2 weeks.
• Episode with temperature above 38 °C during the last 2 weeks.
• Previous diagnosed with chronic lung disease such as cystic fibrosis, primary ciliary dyskinesia, interstitial lung disease, asthma, immunodeficiency, esophagus atresia.
• Cardiac disease, except persisting foramen ovale or ductus arteriosus.
• Severe feeding problems/aspiration.
• Gastroesophageal reflux suspicion or confirmed by ph measurement.
• Suspicion of hypertrophic tonsils or adenoids
• Episodes of bronchopulmonary obstruction suggesting asthma
• Presence of gross neurodevelopmental delay, or suspicion of neurological disease.
• History of known or suspected allergic reactions to amoxicillin-clavulanate or any other betalactam.
• Episodes with haemoptysis and with unknown cause.
• Radiographic changes other than perihilar changes confirmed by x-ray at screening.
• At examination: Digital clubbing, hypoxia, chest wall deformity, dyspnoea at rest.
• Parents unable to speak and/or understand Norwegian language.
• Received systemic antibiotics within the last 6 months before inclusion.
• Participation in another clinical intervention trial.

Where it is running

• Ålesund Hospital — Ålesund, Norway (enrolling)
• Haukeland University Hospital — Bergen, Norway (enrolling)
• Akershus University Hospital — Lillestrøm, Norway (enrolling)
• Oslo University Hospital — Oslo, Norway (enrolling)
• Stavanger University Hospital — Stavanger, Norway (enrolling)
• University Hospital of North-Norway — Tromsø, Norway (enrolling)
• Trondheim University Hospital — Trondheim, Norway (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.